KGKarlijne W. Geijtenbeek

Karlijne W. Geijtenbeek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karlijne W. Geijtenbeek has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Eric A. Reits

    Amsterdam UMC, Department of Medical Biology, Amsterdam, The Netherlands

    2 shared publications
  • Aleksandra E. Bury

    Affiliation Amsterdam UMC Location University of Amsterdam, Medical Biology, Amsterdam, The Netherlands

    1 shared publication
  • Alicia Sanz-Sanz

    Affiliation Amsterdam UMC Location University of Amsterdam, Medical Biology, Amsterdam, The Netherlands

    1 shared publication
  • Arzu Tugce Guler

    Institute for Experiential AI

    1 shared publication
  • Gillian P. Bates

    Affiliation Department of Neurodegenerative Disease, Huntington’s Disease Centre and UK Dementia Research Institute at UCL, Queen Square Institute of Neurology, UCL, London, United Kingdom

    1 shared publication
  • Jolien Janzen

    Affiliation Amsterdam UMC Location University of Amsterdam, Medical Biology, Amsterdam, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Ubiquitin-modifying enzymes in Huntington’s disease

    by Karen A. Sap, Karlijne W. Geijtenbeek, Sabine Schipper-Krom, Arzu Tugce Guler, Eric A. Reits

    Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the N-terminus of the HTT gene. The CAG repeat expansion translates into a polyglutamine expansion in the mutant HTT (mHTT) protein, resulting in intracellular aggregation and neurotoxicity. Lowering the mHTT protein by reducing synthesis or improving degradation would delay or prevent the onset of HD, and the ubiquitin-proteasome system (UPS) could be an important pathway to clear the mHTT proteins prior to aggregation. The UPS is not impaired in HD, and proteasomes can degrade mHTT entirely when HTT is targeted for degradation. However, the mHTT protein is differently ubiquitinated when compared to wild-type HTT (wtHTT), suggesting that the polyQ expansion affects interaction with (de) ubiquitinating enzymes and subsequent targeting for degradation. The soluble mHTT protein is associated with several ubiquitin-modifying enzymes, and various ubiquitin-modifying enzymes have been identified that are linked to Huntington’s disease, either by improving mHTT turnover or affecting overall homeostasis. Here we describe their potential mechanism of action toward improved mHTT targeting towards the proteostasis machinery.


  • Open Access

    Reduction in PA28αβ activation in HD mouse brain correlates to increased mHTT aggregation in cell models

    by Karlijne W. Geijtenbeek, Jolien Janzen, Aleksandra E. Bury, Alicia Sanz-Sanz, Ron A. Hoebe, Marie K. Bondulich, Gillian P. Bates, Eric A. J. Reits, Sabine Schipper-Krom

    Huntington’s disease is an autosomal dominant heritable disorder caused by an expanded CAG trinucleotide repeat at the N-terminus of the Huntingtin (HTT) gene. Lowering the levels of soluble mutant HTT protein prior to aggregation through increased degradation by the proteasome would be a therapeutic strategy to prevent or delay the onset of disease. Native PAGE experiments in HdhQ150 mice and R6/2 mice showed that PA28αβ disassembles from the 20S proteasome during disease progression in the affected cortex, striatum and hippocampus but not in cerebellum and brainstem. Modulating PA28αβ activated proteasomes in various in vitro models showed that PA28αβ improved polyQ degradation, but decreased the turnover of mutant HTT. Silencing of PA28αβ in cells lead to an increase in mutant HTT aggregates, suggesting that PA28αβ is critical for overall proteostasis, but only indirectly affects mutant HTT aggregation.